First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743-Reference-Cited by-同舟云学术

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

Published:2022-05 Issue: Volume:167 Page:8-16
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Scherpereel Arnaud,Antonia Scott,Bautista Yolanda,Grossi Francesco,Kowalski Dariusz,Zalcman Gérard,Nowak Anna K.,Fujimoto Nobukazu,Peters Solange,Tsao Anne S.,Mansfield Aaron S.,Popat Sanjay,Sun Xiaowu,Lawrance Rachael,Zhang Xiaoqing,Daumont Melinda J.,Bennett Bryan,McKenna Mike,Baas Paul

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. ClicaP, Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP);Ruiz-Patino;Thorac Cancer.,2020

2. Immuno-oncology-the new paradigm of lung cancer treatment;Dawe;Curr. Oncol.,2020

3. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life;Park;J. Cancer Surviv.,2020

4. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment;Bibby;Eur. Respir. Rev.,2016

5. Malignant pleural mesothelioma: an epidemiological perspective;Robinson;Ann. Cardiothorac. Surg.,2012

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?;Current Oncology;2024-08-27

2. Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia;Journal of Thoracic Oncology;2024-04

4. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy;Cancers;2023-12-10

5. Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma;International Journal of Clinical Pharmacy;2023-11-22